Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing
Patent
1991-09-19
1994-05-31
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
514415, 514460, 514690, 514922, A61K 4500, A61K 31405, A61K 3135, A61K 3112
Patent
active
053167651
ABSTRACT:
Disclosed are methods for inhibiting the side effects attendant treatment with HMG-CoA reductase inhibitors. Treatment of a patient with and HMG-CoA reductase inhibitor in combination with coenzyme Q.sub.10 provides a reduction in patient cholesterol levels and guards against typical HMG-CoA reductase-inhibitor side effects, most notably liver dysfunction and cardiac dysfunction. The combination of lovastatin, an HMG-CoA reductase inhibitor, and coenzyme Q.sub.10 in ratios of between 1:2 to 1:29 provide significant enhancement of a patient's caridac condition. By way of example, other HMG-CoA reductase inhibitors which may be included in the claimed combinations include pravastatin, compactin, fluvastatin, dalvastatin, simvastatin, BMY 22089, GR-95030, HR-780, CI-981, SQ 33,600, and BMY 22566 and XU-62-320.
REFERENCES:
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4444784 (1984-04-01), Hoffman et al.
patent: 4824669 (1989-04-01), Folkers et al.
patent: 4885167 (1989-12-01), Folkers et al.
patent: 4929437 (1990-05-01), Tobert
patent: 4933165 (1990-06-01), Brown
patent: 5082650 (1992-01-01), Folkers et al.
Alberts et al., (1980), Proc. Natl. Acad. Sci. USA, 77:3957-3961.
Crane, F. L., (1986), Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers and Y. Yamamura, Eds., Amsterdam, The Netherlands: Elsevier Science Publishers, B. V., 5:3-14.
Endo et al., (1976), F.E.B.S. Lett., 72:323-326.
Goodman and Gilman, eds., (1989), In: The Pharmacological Basis of Therapeutics, 7th edition, MacMillan Publishing Co., New York, N.Y. pp. 841-845.
Budavari et al., eds., (1989), In: The Merck Index, 11th edition, Merck and Co., Inc. Publishers, p. 1222.
Langsjoen et al., (1988), Klinische Wochenschrift, 66:583-590.
Langsjoen et al., (1990), The American Journal of Cardiology, 65:521-523.
Balasubramanian, N., et al., (1989), J. Med. Chem., 32:2038-2041.
Roth, B. D. et al., (1991), J. Med. Chem., 34:357-366.
Krause, R. et al., (1990), J. Drug Dev., 3(1): 255-257.
Karanewsky, D. S. et al., (1990), J. Med. Chem. 33:2952-2956.
Folkers et al., (1985), Proc. Natl. Acad. Sci., USA, 82:901.
Merck, Sharp and Dohme, Publishers, (1988) Product Monograph of Mevacor.RTM. (Lovastatin/MSD), pp. 1-77.
Dr. Emile G. Bliznakov and Gerald L. Hunt, The Miracle Nutrient Coenzyme Q.sub.10, Bantam Books, (1986), New York, N.Y., pp. 64-104, p. 123 and pp. 220-232.
Folkers, et al. (1985), Proc. Natl. Acad. Sci., USA, 82:4513-4516.
Willis, et al. (1990), Proc. Natl. Acad. Sci., USA, 87:8928-8930.
Folkers, et al, (1990), Proc. Natl. Acad. Sci., USA, 87:8931-8934.
Folkers et al., (1970), Intnl. J. Vit. Nutr. Res., 40:380-390.
Ganong, W. F., (1981), In: Rev. Med. Phys., Los Altos, Lange Medical Publication, pp. 441-451.
Baker et al., (1981), Elsevier/N.-Holland Biomedical Press, 193-206.
Vadhanavikit et al., (1984), Biochem. Biophys. Res. Commun., 123(3):1165-1169.
Mortensen et al., (1984), Drugs Exptl. Clin. Res., (7):497-502.
Kubicek et al., (Dec. 1966), Aerospace Med., pp. 1208-1212.
DePierre et al., (1977), Ann. Rev. Biochem., 201-262.
Crane et al., (1957), Biochem. Biophys. Acta., 25:220-221.
Saviotti et al., (1984), G. Neuropsichiatr. Eta. Evol., 4/Suppl.1 (67-69), p. 337.
Venco et al., (1984), G. Neuropsychiatr. Eta. Evol., 4//Suppl.1 (61-66), p. 341.
Carafoli et al., (1980), Molec. Aspects of Med., 3:295-429.
Sunamori et al., (1984), In Biomed. and Clin. Aspects of Coenzyme Q, ed. Folkers et al., 4:333-342.
Michelson et al., (1955), Proc. Natl. Acad. Sci., 41:1079-1084.
West, (1966), Annals. N.Y. Accad. of Sciences, 138:4-13.
Welsh et al., (1963), Arch. Int. Med., 112:97-104.
Durnin et al., (1960), J. Iowa Med. Soc., 59:113-115.
Morgan-Hughes, (1983), In Advanced Med., ed. by Saunders, 19:243-260.
Farley et al., (1966), Biochem. and Biophys. Res. Comm., 24:299-303.
Nilsson et al., (1968), Arch. Biochem and Biophys., 133:422-426.
Lenaz et al., (1968), Arch. Biochem. and Biophys., 123-539-550.
Scholler et al., (1968), Int. J. for Vit. Res., 38:362-368.
Littarru et al., (1970), Biochem. and Biophys. Res. Comm., 41:1306-1313.
Danowski et al., (1971), Arch. of Physical Med. and Rehab., 52:193-200.
Sovik et al., (1971), Acta Pediat. Scand., 60:428-432.
Zellweger et al., (1971), Acta. Neurol. Scand., 48:87-101.
Folkers, et al., (1972), Int. J. Vit. Nutr. Res., 42:139-163.
Griggs, (1974), Circ. Res., 34 and 35, pp. II-145-II-150.
Folkers et al., (1974), Proc. Natl. Acad. Sci., USA, 71:2098-2101.
Kuhn et al., (1979), Neurology, 29:1144-1149.
Reeves et al., (1980), Arch. Neurol., 37:273-277.
Hopkins et al., (1981), Annals of Neurol., 10:230-237.
Kishi et al., (1981), Biomed. and Clin. Aspects of Coenzyme Q, vol. 3, Eds. Folkers et al., pp. 67-78.
Couch et al., (1981), ibid, pp. 257-266.
Folkers et al., (1981), ibid, pp. 399-412.
Goldberg et al., (1982), Neurology, 21:1101-1105.
Hawley et al., (1983), Arch. Int. Med., 143:2134-2136.
Bender, (Jan. 1984), Hospital Medicine, pp. 95-125.
Morgan-Hughes et al., (1984), Biomed. and Clin. Aspects of Coenzyme Q, Elsevier Science Pub., 4:417-424.
Ho et al., (1975), Abstract.
Folkers Karl A.
Langsjoen Per H.
Willis Richard A.
Karl Folkers Foundation for Biomedical and Clinical Research
Robinson Douglas W.
Witz Jean C.
LandOfFree
Use of coenzyme Q.sub.10 in combination with HMG-CoA reductase i does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of coenzyme Q.sub.10 in combination with HMG-CoA reductase i, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of coenzyme Q.sub.10 in combination with HMG-CoA reductase i will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1626535